中国癌症杂志 ›› 2023, Vol. 33 ›› Issue (6): 551-559.doi: 10.19401/j.cnki.1007-3639.2023.06.001
收稿日期:
2023-05-10
修回日期:
2023-06-01
出版日期:
2023-06-30
发布日期:
2023-07-26
通信作者:
邵志敏(ORCID:0000-0002-4503-148X),主任医师,教授,复旦大学肿瘤研究所所长、复旦大学乳腺癌研究所所长,复旦大学附属肿瘤医院大外科主任兼乳腺外科主任。
作者简介:
邬思雨(ORCID:0000-0002-8225-552X),博士研究生,住院医师。
WU Siyu(), LI Junjie, SHAO Zhimin()
Received:
2023-05-10
Revised:
2023-06-01
Published:
2023-06-30
Online:
2023-07-26
摘要:
乳腺癌前哨淋巴结活检术(sentinel lymph node biopsy,SLNB)是一项兼具诊断及治疗目的的外科技术,是近年来乳腺外科领域具有里程碑意义的重大进展之一。作为一种腋窝微创外科术式,在乳腺癌综合治疗效果不断提高的背景下,SLNB在近40年的发展呈现出降阶梯趋势,也从侧面反映出乳腺癌作为一种全身性疾病的生物学本质。首先,米兰SLNB185、NSABP-B32等一系列前瞻性随机对照临床试验证实,SLNB可以作为临床腋窝淋巴结阴性早期乳腺癌准确的腋窝分期手段。ACOSOG Z0011、IBCSG 23-01等临床试验结果则进一步丰富了腋窝外科手术降阶梯的概念,前哨淋巴结(sentinel lymph node,SLN)阳性的患者手术范围缩小,即SLN低肿瘤负荷患者中,SLNB可以安全替代腋窝淋巴结清扫(axillary lymph node dissection,ALND)。随后,SLNB以及由此衍生而来的标记淋巴结活检将腋窝微创手术的可行性人群范围进一步扩展到了新辅助治疗的患者。近年来,以EUBREAST-061为代表的回顾性研究及有限的前瞻性研究数据初步证实了腋窝降阶梯治疗在新辅助治疗患者中的肿瘤安全性。未来相关研究将聚焦在筛选寻找有望豁免SLNB的特定低危早期乳腺癌或者新辅助治疗后腋窝成功降期的超级反应者,有待于相关高质量临床研究如SOUND、BOOG 2013-08等临床试验长期随访数据的公布。本文就乳腺癌SLNB的发展历史、最新进展及未来展望进行综述,旨在为广大临床工作者提供参考。
中图分类号:
邬思雨, 李俊杰, 邵志敏. 乳腺癌前哨淋巴结活检术的发展历史及研究进展[J]. 中国癌症杂志, 2023, 33(6): 551-559.
WU Siyu, LI Junjie, SHAO Zhimin. Development history and research progress of sentinel lymph node biopsy in breast cancer[J]. China Oncology, 2023, 33(6): 551-559.
[1] | 马春雷, 斋登. 乳腺癌前哨淋巴结活检现状及研究进展[J]. 疾病监测与控制, 2017, 11(5): 380-382. |
MA C L, ZHAI D. Current status and research progress of Sentinel lymph node biopsy in breast cancer[J]. Dis Monitoring Control, 2017, 11(5): 380-382. | |
[2] | 周嵘, 曾繁余. 乳腺癌前哨淋巴结活检术的研究现状及展望[J]. 世界最新医学信息文摘, 2019, 19(43): 68-70. |
ZHOU R, ZENG F Y. Research status and prospect of sentinel lymph node biopsy for breast cancer[J]. World Latest Med Inform Digest, 2019, 19(43): 68-70. | |
[3] |
段学宁. 乳腺癌手术治疗百年历史回顾与启示[J]. 中国实用外科杂志, 2018, 38(11): 1227-1231.
doi: 10.19538/j.cjps.issn1005-2208.2018.11.03 |
DUAN X N. Centennial review and enlightenment of breast cancer surgery[J]. China Ind Econ, 2018, 38(11): 1227-1231. | |
[4] | 王金礼, 陈登峰. 乳腺癌前哨淋巴结活检术的研究进展[J]. 河南医学研究, 2017, 26(7): 1206-1208. |
WANG J L. CHEN D F. Research progress of sentinel lymph node biopsy in breast cancer[J]. Henan Med Res, 2017, 26(7): 1206-1208. | |
[5] |
KRAG D N, ANDERSON S J, JULIAN T B, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase Ⅲ trial[J]. Lancet Oncol, 2007, 8(10): 881-888.
doi: 10.1016/S1470-2045(07)70278-4 |
[6] |
VERONESI U, PAGANELLI G, VIALE G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer[J]. N Engl J Med, 2003, 349(6): 546-553.
doi: 10.1056/NEJMoa012782 |
[7] |
MANSEL R E, FALLOWFIELD L, KISSIN M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial[J]. J Natl Cancer Inst, 2006, 98(9): 599-609.
doi: 10.1093/jnci/djj158 pmid: 16670385 |
[8] |
PROF, DAVID N, KRAG, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010, 11(10): 927-933.
doi: 10.1016/S1470-2045(10)70207-2 pmid: 20863759 |
[9] |
HUNT K K, BALLMAN K V, MCCALL L M, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial[J]. Ann Surg, 2012, 256(3): 428-436.
pmid: 22868365 |
[10] |
LYMAN G H, GIULIANO A E, SOMERFIELD M R, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer[J]. J Clin Oncol, 2005, 23(30): 7703-7720.
doi: 10.1200/JCO.2005.08.001 pmid: 16157938 |
[11] |
GOLDHIRSCH A, WOOD W C, GELBER R D, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J]. Ann Oncol, 2007, 18(7): 1133-1144.
doi: 10.1093/annonc/mdm271 pmid: 17675394 |
[12] | 王永胜, 欧阳涛, 王启堂, 等. 中国前哨淋巴结活检多中心协作研究CBCSG-001最新资料报告[J]. 中华乳腺病杂志(电子版), 2009, 3(3): 8-12. |
WANG Y S, OUYANG T, WANG Q T, et al. Chinese joint multi-center study of sentinel lymph node biopsy (CBCSG-001): latest news[J]. Chin J Breast Dis Electron Version, 2009, 3(3): 8-12. | |
[13] | 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]. 中国癌症杂志, 2021, 31(10): 954-1040. |
The Society of Breast Cancer China Anti-Cancer Association. Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. | |
[14] |
VAN ZEE K J, MANASSEH D M E, BEVILACQUA J L B, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy[J]. Ann Surg Oncol, 2003, 10(10): 1140-1151.
doi: 10.1245/aso.2003.03.015 pmid: 14654469 |
[15] |
KOHRT H E, OLSHEN R A, BERMAS H R, et al. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients[J]. BMC Cancer, 2008, 8: 66.
doi: 10.1186/1471-2407-8-66 pmid: 18315887 |
[16] |
GIULIANO A E, BALLMAN K V, MCCALL L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial[J]. JAMA, 2017, 318(10): 918-926.
doi: 10.1001/jama.2017.11470 |
[17] |
BARTELS S A L, DONKER M, PONCET C, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial[J]. J Clin Oncol, 2023, 41(12): 2159-2165.
doi: 10.1200/JCO.22.01565 |
[18] |
GALIMBERTI V, COLE B F, VIALE G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial[J]. Lancet Oncol, 2018, 19(10): 1385-1393.
doi: S1470-2045(18)30380-2 pmid: 30196031 |
[19] |
PROF, THORSTEN, KUEHN, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol, 2013, 14(7): 609-618.
doi: 10.1016/S1470-2045(13)70166-9 pmid: 23683750 |
[20] |
BOUGHEY J C, SUMAN V J, MITTENDORF E A, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial[J]. JAMA, 2013, 310(14): 1455-1461.
doi: 10.1001/jama.2013.278932 pmid: 24101169 |
[21] | BOILEAU J F, POIRIER B, BASIK M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol, 2015, 33(3): 258-264. |
[22] |
BOUGHEY J C, SUMAN V J, MITTENDORF E A, et al. Factors affecting sentinel lymph node identification rate after neoadjuvant chemotherapy for breast cancer patients enrolled in ACOSOG Z1071 (Alliance)[J]. Ann Surg, 2015, 261(3): 547-552.
doi: 10.1097/SLA.0000000000000551 pmid: 25664534 |
[23] | BOUGHEY J C, BALLMAN K V, LE-PETROSS H T, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (alliance)[J]. Ann Surg, 2016, 263(4): 802-807. |
[24] |
DONKER M, STRAVER M E, WESSELING J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure[J]. Ann Surg, 2015, 261(2): 378-382.
doi: 10.1097/SLA.0000000000000558 pmid: 24743607 |
[25] |
CAUDLE A S, YANG W T, MITTENDORF E A, et al. Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial[J]. JAMA Surg, 2015, 150(2): 137-143.
doi: 10.1001/jamasurg.2014.1086 pmid: 25517573 |
[26] |
CAUDLE A S, YANG W T, KRISHNAMURTHY S, et al. Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection[J]. J Clin Oncol, 2016, 34(10): 1072-1078.
doi: 10.1200/JCO.2015.64.0094 pmid: 26811528 |
[27] |
SIMONS J M, VAN NIJNATTEN T J A, VAN DER POL C C, et al. Diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy after neoadjuvant chemotherapy in node-positive breast cancer[J]. JAMA Surg, 2022, 157(11): 991-999.
doi: 10.1001/jamasurg.2022.3907 |
[28] |
BRACKSTONE M, BALDASSARRE F G, PERERA F E, et al. Management of the axilla in early-stage breast cancer: Ontario health (cancer care Ontario) and ASCO guideline[J]. J Clin Oncol, 2021, 39(27): 3056-3082.
doi: 10.1200/JCO.21.00934 |
[29] |
VUGTS G, MAASKANT-BRAAT A J, DE ROOS W K, et al. Management of the axilla after neoadjuvant chemotherapy for clinically node positive breast cancer: a nationwide survey study in the Netherlands[J]. Eur J Surg Oncol, 2016, 42(7): 956-964.
doi: 10.1016/j.ejso.2016.03.023 pmid: 27107791 |
[30] |
CAUDLE A S, BEDROSIAN I, MILTON D R, et al. Use of sentinel lymph node dissection after neoadjuvant chemotherapy in patients with node-positive breast cancer at diagnosis: practice patterns of American Society of Breast Surgeons Members[J]. Ann Surg Oncol, 2017, 24(10): 2925-2934.
doi: 10.1245/s10434-017-5958-4 pmid: 28766207 |
[31] |
WU S Y, WANG Y J, ZHANG N, et al. Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis[J]. Ann Surg Oncol, 2018, 25(11): 3150-3157.
doi: 10.1245/s10434-018-6548-9 pmid: 30083833 |
[32] |
WU S, WANG Y, LI J, et al. Subtype-guided 18F-FDG PET/CT in tailoring axillary surgery among patients with node-positive breast cancer treated with neoadjuvant chemotherapy: a feasibility study[J]. Oncologist, 2020, 25(4): e626-e633.
doi: 10.1634/theoncologist.2019-0583 |
[33] |
WU S Y, LI J W, WU H L, et al. Accuracy of ultrasound-guided targeted fine-needle aspiration in assessing nodal response in node-positive breast cancer after neoadjuvant chemotherapy: prospective feasibility study[J]. Br J Surg, 2022, 109(12): 1194-1197.
doi: 10.1093/bjs/znac277 |
[34] | WU S Y, LI J W, ZHANG Y, et al. Repeated core needle biopsy and targeted fine-needle aspiration to optimize axillary surgery after neoadjuvant chemotherapy in node-positive breast cancer: a prospective clinical study[J]. Br J Surg, 2023: znad106. |
[35] |
PILTIN M A, HOSKIN T L, DAY C N, et al. Oncologic outcomes of sentinel lymph node surgery after neoadjuvant chemotherapy for node-positive breast cancer[J]. Ann Surg Oncol, 2020, 27(12): 4795-4801.
doi: 10.1245/s10434-020-08900-0 |
[36] |
BARRIO A V, MONTAGNA G, MAMTANI A, et al. Nodal recurrence in patients with node-positive breast cancer treated with sentinel node biopsy alone after neoadjuvant chemotherapy-a rare event[J]. JAMA Oncol, 2021, 7(12): 1851-1855.
doi: 10.1001/jamaoncol.2021.4394 pmid: 34617979 |
[37] |
MARTELLI G, BARRETTA F, MICELI R, et al. Sentinel node biopsy alone or with axillary dissection in breast cancer patients after primary chemotherapy: long-term results of a prospective interventional study[J]. Ann Surg, 2022, 276(5): e544-e552.
doi: 10.1097/SLA.0000000000004562 |
[38] | WU S Y, LI J W, WANG Y J, et al. Clinical feasibility and oncological safety of non-radioactive targeted axillary dissection after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: a prospective diagnostic and prognostic study[J]. Int J Surg, 2023. Online ahead of print. |
[39] |
BURSTEIN H J, CURIGLIANO G, LOIBL S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol, 2019, 30(10): 1541-1557.
doi: S0923-7534(19)60978-6 pmid: 31987446 |
[40] |
JATOI I, KUNKLER I H. Omission of sentinel node biopsy for breast cancer: historical context and future perspectives on a modern controversy[J]. Cancer, 2021, 127(23): 4376-4383.
doi: 10.1002/cncr.33960 pmid: 34614216 |
[41] |
TADROS A B, YANG W T, KRISHNAMURTHY S, et al. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery[J]. JAMA Surg, 2017, 152(7): 665-670.
doi: 10.1001/jamasurg.2017.0562 pmid: 28423171 |
[42] |
BARRON A U, HOSKIN T L, DAY C N, et al. Association of low nodal positivity rate among patients with ERBB2-positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy[J]. JAMA Surg, 2018, 153(12): 1120.
doi: 10.1001/jamasurg.2018.2696 pmid: 30193375 |
[43] |
FAYANJU O M, REN Y, THOMAS S M, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20 000 breast cancer patients in the national cancer data base (NCDB)[J]. Ann Surg, 2018, 268(4): 591-601.
doi: 10.1097/SLA.0000000000002953 |
[44] |
PFOB A, SIDEY-GIBBONS C, RAUCH G, et al. Intelligent vacuum-assisted biopsy to identify breast cancer patients with pathologic complete response (ypT0 and ypN0) after neoadjuvant systemic treatment for omission of breast and axillary surgery[J]. J Clin Oncol, 2022, 40(17): 1903-1915.
doi: 10.1200/JCO.21.02439 |
[1] | 王若曦, 吉芃, 龚悦, 陈盛. HER2低表达乳腺癌新辅助化疗效果及其预后特征:一项单中心回顾性研究[J]. 中国癌症杂志, 2023, 33(7): 686-692. |
[2] | 毕钊, 王永胜. 1~2枚前哨淋巴结阳性早期乳腺癌患者治疗策略降阶梯新理念[J]. 中国癌症杂志, 2023, 33(6): 560-565. |
[3] | 赵谦, 凌云霄, 柳光宇. 乳腺癌患者保乳手术后再次前哨淋巴结活检的最新研究进展及展望[J]. 中国癌症杂志, 2023, 33(6): 566-573. |
[4] | 丛斌斌, 曹晓珊, 王春建, 邱鹏飞, 孙晓, 陈鹏, 刘雁冰, 赵桐, 张朝蓬, 石志强, 毕钊, 王永胜. 临床查体阴性但超声检查及穿刺确诊腋窝淋巴结转移的乳腺癌前哨淋巴结活检的可行性分析[J]. 中国癌症杂志, 2023, 33(6): 574-580. |
[5] | 任恒宇, 郝爽, 陈嘉健, 杨犇龙, 曹阿勇, 柳光宇, 邵志敏, 吴炅. 国内外乳房重建研究的现状和重点:一项文献计量学研究[J]. 中国癌症杂志, 2023, 33(6): 581-588. |
[6] | 陈璐艳, 王丽雪, 傅佩芬. 新发Ⅳ期乳腺癌患者手术价值探讨[J]. 中国癌症杂志, 2023, 33(5): 431-436. |
[7] | 杨闻箫, 国琳玮, 凌泓, 胡欣. 基于免疫微环境特征的曲妥珠单抗与免疫治疗联合应用预测模型[J]. 中国癌症杂志, 2023, 33(5): 484-498. |
[8] | 王辉, 王霞, 郜意, 胥婧, 余小娟, 范芳琴, 丁焱, 康玉. 遗传性乳腺癌-卵巢癌综合征患者一级亲属接受基因筛查的现状及影响因素研究[J]. 中国癌症杂志, 2023, 33(5): 499-505. |
[9] | 陈君瑶, 张文涛, 刘巧, 聂建云. 老年三阴性乳腺癌患者的临床困境和系统治疗策略[J]. 中国癌症杂志, 2023, 33(5): 506-516. |
[10] | 陈红, 陈俊霞. 环状RNA hsa_circ_0001573对乳腺癌细胞生物学行为的影响及机制研究[J]. 中国癌症杂志, 2023, 33(4): 342-353. |
[11] | 毕钊, 陈鹏, 邱鹏飞, 陈玉光, 王永胜. 乳腺癌新辅助治疗后腋窝淋巴结转移情况分析[J]. 中国癌症杂志, 2023, 33(4): 361-367. |
[12] | 曹晓珊, 丛斌斌. 三阳性乳腺癌内分泌治疗联合靶向治疗的研究进展[J]. 中国癌症杂志, 2023, 33(3): 288-292. |
[13] | 邵志博, 杨犇龙, 吴炅. 2022年中国乳腺癌重要临床试验成果及最新进展[J]. 中国癌症杂志, 2023, 33(2): 103-109. |
[14] | 张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116. |
[15] | 杨犇龙, 焦得闯, 陈嘉健, 王春建, 金利丹, 赵文和, 高学强, 王海波, 李珺, 赵海东, 吴迪, 范志明, 王淑君, 刘真真, 王永胜, 吴炅. 示踪用盐酸米托蒽醌注射液与核素用于乳腺癌前哨淋巴结活检的疗效对比研究[J]. 中国癌症杂志, 2023, 33(2): 126-133. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||
地址:上海市徐汇区东安路270号复旦大学附属肿瘤医院10号楼415室
邮编:200032 电话:021-64188274 E-mail:zgazzz@china-oncology.com
访问总数:; 今日访问总数:; 当前在线人数:
本系统由北京玛格泰克科技发展有限公司设计开发 技术支持:support@magtech.com.cn